China’s ETF markets recorded a net inflow of 3.6 billion yuan, with bond ETFs leading at +12.92 billion yuan, while stock ETFs saw -10.81 billion yuan in outflows. Sector-wise, Hong Kong-listed biotech ETFs dominated inflows, with the Hong Kong Stock Exchange Innovation Drug ETF (513120) attracting 521 million yuan, followed by the Hong Kong Stock Connect Innovation Drug ETF (159570, +137 million yuan) and Saudi ETF (159329, +133 million yuan).
Conversely, broad-market equity ETFs faced significant redemptions, led by the Shanghai-Shenzhen 300 ETF (510300, -761 million yuan), Science and Technology Innovation 50 ETF (588000, -755 million yuan), and Shanghai Stock Exchange 50 ETF (510050, -735 million yuan). The divergence highlights a rotation from large-cap indices to niche themes, particularly offshore healthcare and Middle East exposure.
The bond ETF surge (+12.92 billion yuan) underscores defensive positioning, while commodity ETFs saw modest inflows (+77 million yuan). QDII ETFs recorded -891 million yuan outflows, reflecting global market caution.
Related topics：
